Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) candidate from China's Simcere in a deal that would be worth up to €1.05 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results